NASDAQ: NAUTNautilus Biotechnology Inc Stock
$2.17-0.08 (-3.56%)
Updated Jun 16, 2026
NAUT Price
$2.17
Fair Value Price
-$0.14
Market Cap
$275.76M
52 Week Low
$0.62
52 Week High
$4.31
P/E
-4.72x
P/B
1.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$50M
Beta
1.62
Next Earnings
Jul 30, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NAUT Overview
Nautilus Biotechnology, Inc. is an emerging life sciences firm dedicated to pioneering a platform technology aimed at quantifying and comprehensively understanding the intricate complexities of the proteome. Their flagship offering, the Nautilus Platform, is an integrated proteomics system. It provides a complete, end-to-end solution, including specialized instruments, essential consumables, and advanced software for data analysis. Based in Seattle, Washington, the company was established in 2016.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NAUT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NAUT
Ranked#171 of 462
Ranked#171 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important NAUT news, forecast changes, insider trades & much more!
NAUT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NAUT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAUT ($2.17) is overvalued by 1,653.95% relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NAUT ($2.17) is not significantly undervalued (1,653.95%) relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NAUT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NAUT due diligence checks available for Premium users.
Valuation
NAUT fair value
Fair Value of NAUT stock based on Discounted Cash Flow (DCF)
Price
$2.17
Fair Value
-$0.14
Undervalued by
1,653.95%
NAUT ($2.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NAUT ($2.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NAUT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NAUT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.72x
Industry
16.03x
Market
13.25x
NAUT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.91x
Industry
4.86x
NAUT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NAUT's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.7M
Profit Margin
0%
NAUT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$177.8M
Liabilities
$33.4M
Debt to equity
0.23
NAUT's short-term assets ($98.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAUT's short-term assets ($98.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAUT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NAUT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.1M
Investing
$14.2M
Financing
$1.1M
NAUT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NAUT vs Biotech Stocks
Nautilus Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.